StockMirror — Stock Screener

ONESOURCE Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

OneSource Specialty Pharma reported strong Q2 FY27 results with 37% YoY revenue growth to over INR5bn, 53% YoY EBITDA growth, and 400 bps QoQ margin expansion. Growth was driven by new DDC capacity, strong semaglutide demand, and new customer wins. Management reaffirmed FY28 guidance of $400mn revenue and $160mn EBITDA, with all three DDC lines to be operational. Biologics is emerging as a key growth pillar. Key risks include geopolitical disruptions and qualification timelines.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized growth through capacity expansion and new launches while also highlighting margin expansion from operating leverage.

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (ONESOURCE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More